

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Novartis Bioventures Ltd</u>  (Last) (First) (Middle) <u>C/O NOVARTIS INTERNATIONAL AG</u> <u>WSJ-200.220</u>  (Street) <u>BASEL V8 CH-4002</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>AILERON THERAPEUTICS INC [ ALRN ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>07/05/2017</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/05/2017		C		2,277,515	A	(1)	2,277,515	D <sup>(2)</sup>	
Common Stock	07/05/2017		P		266,667 <sup>(3)</sup>	A	\$15	2,544,182	D <sup>(2)</sup>	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series C Preferred Stock	(1)	07/05/2017		C			2,967,025	(1)	(1)	Common Stock	298,583	\$0.00	0	D <sup>(2)</sup>	
Series C-2 Preferred Stock	(1)	07/05/2017		C			4,238,607	(1)	(1)	Common Stock	426,547	\$0.00	0	D <sup>(2)</sup>	
Series D Preferred Stock	(1)	07/05/2017		C			6,781,770	(1)	(1)	Common Stock	682,476	\$0.00	0	D <sup>(2)</sup>	
Series E-2 Preferred Stock	(1)	07/05/2017		C			2,644,558	(1)	(1)	Common Stock	266,132	\$0.00	0	D <sup>(2)</sup>	
Series E-3 Preferred Stock	(1)	07/05/2017		C			2,293,829	(1)	(1)	Common Stock	230,837	\$0.00	0	D <sup>(2)</sup>	
Series F Preferred Stock	(1)	07/05/2017		C			3,705,882	(1)	(1)	Common Stock	372,937	\$0.00	0	D <sup>(2)</sup>	

1. Name and Address of Reporting Person\*  
Novartis Bioventures Ltd  
  
 (Last) (First) (Middle)  
C/O NOVARTIS INTERNATIONAL AG  
WSJ-200.220  
  
 (Street)  
BASEL V8 CH-4002  
  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
NOVARTIS AG  
  
 (Last) (First) (Middle)  
LICHTSTRASSE 35

